COVID-19 Treatment Guidelines: Do They Really Reflect Best Medical Practices to Manage the Pandemic?

被引:32
作者
Jirjees, Feras [1 ]
Saad, Ali K. [2 ]
Al Hano, Zahraa [1 ]
Hatahet, Taher [3 ,4 ]
Al Obaidi, Hala [5 ]
Dallal Bashi, Yahya H. [3 ]
机构
[1] Univ Sharjah, Coll Pharm, Sharjah, U Arab Emirates
[2] United Arab Emirates Univ, Coll Med & Hlth Sci, Al Ain, U Arab Emirates
[3] Queens Univ Belfast, Sch Pharm, Belfast, Antrim, North Ireland
[4] China Med Univ, Queens Univ Belfast Joint Coll CQC, 77 Puhe Rd, Shenyang 110122, Peoples R China
[5] City Univ Coll Ajman, Dept Pharm, Ajman, U Arab Emirates
关键词
COVID-19 treatment guidelines; therapeutics guidelines; medications; pharmacological management; CORONAVIRUS DISEASE 2019; INTERFERON BETA-1B; OPEN-LABEL; HYDROXYCHLOROQUINE; RIBAVIRIN; PHARMACOKINETICS; AZITHROMYCIN; CHLOROQUINE; COMBINATION; PNEUMONIA;
D O I
10.3390/idr13020029
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
SARS-CoV-2 (COVID-19) has been changing the world since December 2019. A comprehensive search into many COVID-19 treatment guidelines was conducted and reported in this article. This is a review paper to probe differences in COVID-19 managing strategies and explore the most common treatment plans among countries. Published guidelines from 23 countries and three references guidelines-until the end of 2020-were included in this article. The majority of COVID-19 treatment options were reported in this review and it includes antiviral drugs, antimalarial drugs, antibiotics, corticosteroids, immunotherapy, anticoagulants, and other pharmacological treatment. The presence of such information from different countries in a single comprehensive review article could help in understanding and speculation of variation in the recommended treatment in each country. This might be related to the cost of medications, the access to the medications, availability of medication that could potentially be useful in managing COVID-19 cases, and the availability/capacity of healthcare facilities. Finally, although there are various treatment groups listed in the published therapeutic guidelines worldwide, unfortunately, there is no evidence for effectiveness of most of these medications in reducing the COVID-19 mortality curve over more than one year of this global pandemic.
引用
收藏
页码:259 / 284
页数:26
相关论文
共 140 条
[1]   Lipid Management in Patients Who Have HIV and Are Receiving HIV Therapy [J].
Aberg, Judith A. .
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2009, 38 (01) :207-+
[2]   Dysregulation of type I interferon responses in COVID-19 [J].
Acharya, Dhiraj ;
Liu, GuanQun ;
Gack, Michaela U. .
NATURE REVIEWS IMMUNOLOGY, 2020, 20 (07) :397-398
[3]  
Agencia Espanola de Medicamentos y Productos Sanitarios, 2020, TRAT DISP SUJ COND E
[4]  
Agenzia Italiana del Farmaco, 2020, EM COVID 19
[5]  
Alborghetti L., 2020, IL 6 SIGNALLING PATH, DOI [10.1101/2020.04.01.20048561, 10.1101/ 2020.04.01.20048561, DOI 10.1101/2020.04.01.20048561]
[6]   COVID-19: lambda interferon against viral load and hyperinflammation [J].
Andreakos, Evangelos ;
Tsiodras, Sotirios .
EMBO MOLECULAR MEDICINE, 2020, 12 (06)
[7]   Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus [J].
Angel Martinez, Miguel .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (05)
[8]   Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance [J].
不详 .
PEDIATRIA I MEDYCYNA RODZINNA-PAEDIATRICS AND FAMILY MEDICINE, 2020, 16 (01) :9-26
[9]  
[Anonymous], 2020, NATL COVID 19 CLIN E
[10]  
[Anonymous], 2021, PRESCRIPTION DRUG IN